Overview
At GenThera, we are committed to revolutionizing the treatment landscape for individuals suffering from rare genetic disorders. Our proprietary platform leverages cutting-edge CRISPR technology to target and modify genes responsible for these conditions, offering hope where traditional therapies fall short. Since our inception in 2024, we have developed a promising lead candidate, GT-101, which has shown substantial efficacy in preclinical trials for a rare metabolic disorder. We are now at a pivotal stage where investment will allow us to advance to human clinical trials, thereby unlocking vast market opportunities. Our team, which includes industry veterans with deep expertise in genetic research and drug development, is poised to guide GenThera through this crucial growth phase. We have established partnerships with leading academic institutions for our research initiatives, and our initial funding rounds have successfully validated our approach and technology. However, to maintain momentum and achieve our goals, we require additional capital. We have tested the direction and now need funding to turn early traction into a stronger business. GenThera is pioneering advanced geneti…
Use of funds
The $2,500,000 we are seeking will primarily be allocated as follows:
- Clinical Trial Costs: $1,200,000 for patient recruitment, monitoring, and data analysis.
- R&D: $800,000 to further develop our gene editing platform and improve our therapies.
- Operational Costs: $300,000 for expanding our team with experienced regulatory and clinical staff.
- Marketing and Outreach: $200,000 to build awareness and establish relationships with healthcare providers and institutions.
- Infrastructure: $200,000 for laboratory enhancement and equipment upgrades.
Open case
Open this case to get the detailed business plan and direct contact with the founder or seeker.